William Blair Starts Vor Biopharma, Inc. (VOR) at Outperform
William Blair analyst Myles Minter initiates coverage on Vor Biopharma, Inc. (NASDAQ: VOR) with a Outperform rating.
The analyst comments "We are initiating coverage of Xilio Therapeutics (XLO) with an Outperform rating and a price target of $16. Our thesis is predicated on three key points: 1) Xilio has administered its masking technology in multiple clinical programs with manageable safety and tolerability, 2) Xilio can leverage its current financial outlook to transition from legacy programs into modalities with a higher likelihood of success, namely masked T-cell engagers (TCEs), and 3) collaborations with pharma provide a pragmatic path forward to maximize value of existing programs and reinvest in the internally owned pipeline.Our constructive view is balanced by a clinical pipeline that has faced developmental hurdles following Phase 1 in multiple assets, which has forced Xilio to shift its R&D focus to early assets and crowded indications."
For an analyst ratings summary and ratings history on Vor Biopharma, Inc. click here. For more ratings news on Vor Biopharma, Inc. click here.
Shares of Vor Biopharma, Inc. closed at $19.03 yesterday.